Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1160/TH12-07-0484 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies.
Nefrologia (Engl Ed)
December 2024
Department of Medical Doctor Study Program, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia.
Background: Chronic kidney disease (CKD) is a major global health problem. Hyperphosphatemia is frequent in CKD and a reason for increased morbidity and mortality as it generates hyperparathyroidism, high fibroblast growth factor 23 (FGF23), and hypocalcemia. Available hyperphosphatemia therapies still have limitations, including risk of metal overload, cardiovascular calcification, and systemic adverse effects (AEs).
View Article and Find Full Text PDFGla-Rich Protein Is Associated with Vascular Calcification, Inflammation, and Mineral Markers in Peritoneal Dialysis Patients.
J Clin Med
December 2024
Centre of Marine Sciences, University of Algarve, 8005-139 Faro, Portugal.
: Vascular calcification (VC) is a crucial risk factor for cardiovascular diseases (CVD), particularly in chronic kidney disease (CKD) populations. However, the specific relationship between VC and end-stage renal disease (ESRD) patients undergoing peritoneal dialysis (PD) remains to be fully understood. The identification of new biomarkers to improve VC diagnosis and monitoring would significantly impact cardiovascular risk management in these high-risk patients.
View Article and Find Full Text PDFUnderstanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications.
Int J Mol Sci
December 2024
Department of Medical and Surgical Sciences, "Magna Grecia" University, 88100 Catanzaro, Italy.
Vascular calcification (VC) is a biological phenomenon characterized by an accumulation of calcium and phosphate deposits within the walls of blood vessels causing the loss of elasticity of the arterial walls. VC plays a crucial role in the incidence and progression of chronic kidney disease (CKD), leading to a significant increase in cardiovascular mortality in these patients. Different conditions such as age, sex, dyslipidemia, diabetes, and hypertension are the main risk factors in patients affected by chronic kidney disease.
View Article and Find Full Text PDFTranscriptional Regulation of the Human MGP Promoter: Identification of Downstream Repressors.
Int J Mol Sci
November 2024
Center of Marine Sciences (CCMAR), University of Algarve, 8005-139 Faro, Portugal.
Matrix Gla protein (MGP) is a vitamin K-dependent γ-carboxylated protein that was initially identified as a physiological inhibitor of ectopic calcification, primarily affecting cartilage and the vascular system. Mutations in the gene were found to be responsible for the Keutel syndrome, a condition characterized by abnormal calcifications in the cartilage, lungs, brain, and vascular system. has been shown to be dysregulated in several tumors, including cervical, ovarian, urogenital, and breast cancers.
View Article and Find Full Text PDFUpdate on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease.
Expert Opin Pharmacother
December 2024
Department of Nephrology and Dialysis, past Drectoor, Alessandro Manzoni Hospital, ASST Lecco, Lecco, Italy.
Introduction: Hyperphosphatemia in advanced CKD often accompanies high PTH and FGF23 levels, impaired bone mineralization, ectopic calcifications, and increased cardiovascular risks. Novel treatments are now available to lower serum phosphorus effectively. However, safety, tolerability, and patient adherence must be evaluated to determine the best therapeutic option for hyperphosphatemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!